{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:34:17Z","timestamp":1779251657682,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41375-025-02784-3","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T12:49:00Z","timestamp":1760359740000},"page":"2858-2861","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Does everyone with newly-diagnosed, untreated acute myeloid leukaemia need remission-induction chemotherapy before advancing to a transplant?"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2237-6733","authenticated-orcid":false,"given":"E.","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. P.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"2784_CR1","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/bjh.16355","volume":"188","author":"J Loke","year":"2020","unstructured":"Loke J, Malladi R, Moss P, Craddock C. The role of allogeneic stem cell transplantation in the management of acute myeloid leukaemia: a triumph of hope and experience. Br J Haematol. 2020;188:129\u201346.","journal-title":"Br J Haematol"},{"key":"2784_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2784_CR3","first-page":"46","volume":"75","author":"HM Kantarjian","year":"2025","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, et al. Acute myeloid leukemia management and research in 2025. CA Cancer J Clin. 2025;75:46\u201367.","journal-title":"CA Cancer J Clin"},{"key":"2784_CR4","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/ajh.27625","volume":"100","author":"S Shimony","year":"2025","unstructured":"Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2025 update on diagnosis, risk-stratification, and management. Am J Hematol. 2025;100:860\u201391.","journal-title":"Am J Hematol"},{"key":"2784_CR5","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1038\/s41375-025-02560-3","volume":"39","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2025","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Phillips GL, Pardee TS, Lazarus HM, Gale RP. Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given. Leukemia. 2025;39:1053\u20135.","journal-title":"Leukemia"},{"key":"2784_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3324\/haematol.2017.178442","volume":"103","author":"T Herold","year":"2018","unstructured":"Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, et al. A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia. Haematologica. 2018;103:456\u201365.","journal-title":"Haematologica"},{"key":"2784_CR7","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2021.280027","volume":"108","author":"JN Eckardt","year":"2023","unstructured":"Eckardt JN, R\u00f6llig C, Metzeler K, Kramer M, Stasik S, Georgi JA, et al. Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. Haematologica. 2023;108:690\u2013704.","journal-title":"Haematologica"},{"key":"2784_CR8","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/s41409-019-0729-4","volume":"55","author":"M Othus","year":"2020","unstructured":"Othus M, Gale RP, Hourigan CS, Walter RB. Statistics and measurable residual disease (MRD) testing: uses and abuses in hematopoietic cell transplantation. Bone Marrow Transplant. 2020;55:843\u201350.","journal-title":"Bone Marrow Transplant"},{"key":"2784_CR9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41409-018-0424-x","volume":"55","author":"C Zheng","year":"2020","unstructured":"Zheng C, Dai R, Gale RP, Zhang MJ. Causal inference in randomized clinical trials. Bone Marrow Transplant. 2020;55:4\u20138.","journal-title":"Bone Marrow Transplant"},{"key":"2784_CR10","doi-asserted-by":"publisher","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","volume":"11","author":"M Stelljes","year":"2024","unstructured":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, M\u00fcller LP, Schmid C, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024;11:e324\u201335.","journal-title":"Lancet Haematol"},{"key":"2784_CR11","doi-asserted-by":"publisher","unstructured":"Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Mueller LP, Schmid C, et al. Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2025028730.","DOI":"10.1182\/blood.2025028730"},{"key":"2784_CR12","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb HJ. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23:5675\u201387.","journal-title":"J Clin Oncol"},{"key":"2784_CR13","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","volume":"108","author":"C Schmid","year":"2006","unstructured":"Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, et al. Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108:1092\u20139.","journal-title":"Blood"},{"key":"2784_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1002\/ajh.25004","volume":"93","author":"J Decroocq","year":"2018","unstructured":"Decroocq J, Itzykson R, Vigouroux S, Michallet M, Yakoub-Agha I, Huynh A, et al. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia: a study from the Soci\u00e9t\u00e9 Francophone de Greffe de Moelle et de Th\u00e9rapie Cellula. Am J Hematol. 2018;93:416\u201323.","journal-title":"Am J Hematol"},{"key":"2784_CR15","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2020","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Labopin M, Tischer J, Brecht A, Ganser A, Finke J, et al. FLAMSA-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed\/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2020;26:2165\u201373.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2784_CR16","doi-asserted-by":"publisher","first-page":"524","DOI":"10.3324\/haematol.2017.187450","volume":"104","author":"E Brissot","year":"2019","unstructured":"Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, et al. Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed\/ refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT. Haematologica. 2019;104:524\u201332.","journal-title":"Haematologica"},{"key":"2784_CR17","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","volume":"36","author":"JE Lancet","year":"2018","unstructured":"Lancet JE, Uy GL, Cortes JE, Newell LF, Lin TL, Ritchie EK, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018;36:2684\u201392.","journal-title":"J Clin Oncol"},{"key":"2784_CR18","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1182\/bloodadvances.2021005335","volume":"6","author":"D Mart\u00ednez-Cuadr\u00f3n","year":"2022","unstructured":"Mart\u00ednez-Cuadr\u00f3n D, Meg\u00edas-Vericat JE, Serrano J, Mart\u00ednez-S\u00e1nchez P, Rodr\u00edguez-Arbol\u00ed E, Gil C, et al. Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Adv. 2022;6:1278\u201395.","journal-title":"Blood Adv"},{"key":"2784_CR19","doi-asserted-by":"crossref","unstructured":"Nagler A, Savani BN, Labopin M, Polge E, Passweg J, Finke J, et al. Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis. Lancet Haematol. 2015;2:e384-92.","DOI":"10.1016\/S2352-3026(15)00146-5"},{"key":"2784_CR20","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Labopin M, Eder M, Brecht A, Blau IW, Huynh A, et al. Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed\/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplant. 2022;57:934\u201341.","DOI":"10.1038\/s41409-022-01611-y"},{"key":"2784_CR21","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1200\/JCO.21.00960","volume":"39","author":"NJ Short","year":"2021","unstructured":"Short NJ, Kantarjian H. When less is more: reevaluating the role of intensive chemotherapy for older adults with acute myeloid leukemia in the modern era. J Clin Oncol. 2021;39:3104\u20138.","journal-title":"J Clin Oncol"},{"key":"2784_CR22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1002\/ajh.26395","volume":"97","author":"K Sasaki","year":"2022","unstructured":"Sasaki K, Kadia T, Begna K, DiNardo CD, Borthakur G, Short NJ, et al. Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy. Am J Hematol. 2022;97:68\u201378.","journal-title":"Am J Hematol"},{"key":"2784_CR23","doi-asserted-by":"publisher","first-page":"e35618","DOI":"10.1002\/cncr.35618","volume":"131","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2025","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Rodr\u00edguez-Veiga R, Soria-Saldise E, Bergua JM, Caballero-Vel\u00e1zquez T, Arn\u00e1n M, et al. A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX. Cancer. 2025;131:e35618.","journal-title":"Cancer"},{"key":"2784_CR24","doi-asserted-by":"publisher","first-page":"2578","DOI":"10.1182\/blood.V89.7.2578","volume":"89","author":"JE Anderson","year":"1997","unstructured":"Anderson JE, Gooley TA, Schoch G, Anasetti C, Bensinger WI, Clift RA, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578\u201385.","journal-title":"Blood"},{"key":"2784_CR25","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.bbmt.2011.09.006","volume":"18","author":"C Saure","year":"2012","unstructured":"Saure C, Schroeder T, Zohren F, Groten A, Bruns I, Czibere A, et al. Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen. Biol Blood Marrow Transpl. 2012;18:466\u201372.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2784_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01233-9","volume":"15","author":"R Xue","year":"2025","unstructured":"Xue R, Dai M, Jiang E, Ou X, Huang F, Fan Z, et al. Effect of pre-transplant cytoreductive therapy on the outcomes of patients with MDS or secondary AML evolving from MDS undergoing allo-HSCT: a secondary analysis of an RCT. Blood Cancer J. 2025;15:21.","journal-title":"Blood Cancer J"},{"key":"2784_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/sj.leu.2403640","volume":"19","author":"K Nakai","year":"2005","unstructured":"Nakai K, Kanda Y, Fukuhara S, Sakamaki H, Okamoto S, Kodera Y, et al. Value of chemotherapy before allogeneic hematopoietic stem cell transplantation from an HLA-identical sibling donor for myelodysplastic syndrome. Leukemia. 2005;19:396\u2013401.","journal-title":"Leukemia"},{"key":"2784_CR28","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1200\/JCO.2012.48.0525","volume":"31","author":"EP Alessandrino","year":"2013","unstructured":"Alessandrino EP, Della Porta MG, Pascutto C, Bacigalupo A, Rambaldi A. Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome? J Clin Oncol. 2013;31:2760\u20131.","journal-title":"J Clin Oncol"},{"key":"2784_CR29","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","volume":"25","author":"T Schroeder","year":"2019","unstructured":"Schroeder T, Wegener N, Lauseker M, Rautenberg C, Nachtkamp K, Schuler E, et al. Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia. Biol Blood Marrow Transpl. 2019;25:1550\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2784_CR30","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/j.bbmt.2019.06.016","volume":"25","author":"N Kr\u00f6ger","year":"2019","unstructured":"Kr\u00f6ger N. Induction, bridging, or straight ahead: the ongoing dilemma of allografting in advanced myelodysplastic syndrome. Biol Blood Marrow Transpl. 2019;25:e247\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"2784_CR31","doi-asserted-by":"crossref","unstructured":"Stelmach P, Trumpp A. Leukemic stem cells and therapy resistance in acute myeloid leukemia. Haematologica. 2023;108:353\u201366.","DOI":"10.3324\/haematol.2022.280800"},{"key":"2784_CR32","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Gale RP, Gormley NJ, Ossenkoppele GJ, Walter RB. Measurable residual disease testing in acute myeloid leukaemia. Leukemia. 2017;31:1482\u201390.","DOI":"10.1038\/leu.2017.113"},{"key":"2784_CR33","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nature10738","volume":"481","author":"L Ding","year":"2012","unstructured":"Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012;481:506\u201310.","journal-title":"Nature"},{"key":"2784_CR34","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1002\/gcc.22806","volume":"58","author":"S Vosberg","year":"2019","unstructured":"Vosberg S, Greif PA. Clonal evolution of acute myeloid leukemia from diagnosis to relapse. Genes Chromosomes Cancer. 2019;58:839\u201349.","journal-title":"Genes Chromosomes Cancer"},{"key":"2784_CR35","first-page":"3543","volume":"109","author":"A Bataller","year":"2024","unstructured":"Bataller A, Kantarjian H, Bazinet A, Kadia T, Daver N, DiNardo CD, et al. Outcomes and genetic dynamics of acute myeloid leukemia at first relapse. Haematologica. 2024;109:3543\u201356.","journal-title":"Haematologica"},{"key":"2784_CR36","doi-asserted-by":"crossref","unstructured":"Winters AC, Bosma G, Abbott D, Minhajuddin M, Jordan C, Pollyea DA, et al. Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax + azacitidine versus intensive chemotherapy. Transplant Cell Ther. 2022;28:694.e1\u2013694.e9.","DOI":"10.1016\/j.jtct.2022.07.022"},{"key":"2784_CR37","doi-asserted-by":"crossref","unstructured":"Lu J, Xue SL, Wang Y, He XF, Hu XH, Miao M, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood. 2025;145:2645\u201355.","DOI":"10.1182\/blood.2024027217"},{"key":"2784_CR38","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s41375-024-02214-w","volume":"38","author":"RP Gale","year":"2024","unstructured":"Gale RP, Phillips GL, Lazarus HM. A modest proposal to the transplant publik to prevent harm to people with acute myeloid leukaemia in 1st complete remission cured by chemotherapy. Leukemia. 2024;38:1663\u20136.","journal-title":"Leukemia"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02784-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02784-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:45Z","timestamp":1763629845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02784-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2784"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02784-3","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"assertion":[{"value":"30 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ER-A was a consultant to Astellas, Laboratoires Delbert, Kura Oncology, Servier, and Syndax Pharmaceuticals, and received travel grants and\/or speaker fees from Jazz\u00a0Pharmaceuticals, Astellas, AbbVie, Gilead, and Eurocept. RPG is a consultant to Antengene Biotech LLC; consultant, Shenzhen TargetRx; Medical Director, FFF Enterprises Inc; speaker for Janssen, BeiGene and Hengrui Pharma; Board of Directors, Russian Foundation for Cancer Research Support; Scientific Advisory Board, StemRad Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}